Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and axial involvement: results from two phase 3 studies

Abstract Background The objective of this post-hoc analysis was to assess the efficacy and safety of upadacitinib in psoriatic arthritis (PsA) patients with axial involvement. Methods Post-hoc analysis of SELECT-PsA 1 and SELECT-PsA 2 in patients randomized to upadacitinib 15 mg (UPA15), placebo (sw...

Full description

Bibliographic Details
Main Authors: Xenofon Baraliakos, Roberto Ranza, Andrew Östör, Francesco Ciccia, Laura C. Coates, Simona Rednic, Jessica A. Walsh, Kevin Douglas, Tianming Gao, Koji Kato, In-Ho Song, Fabiana Ganz, Atul Deodhar
Format: Article
Language:English
Published: BMC 2023-04-01
Series:Arthritis Research & Therapy
Subjects:
Adalimumab
Ankylosing Spondylitis Disease Activity Score (ASDAS)
Axial involvement
Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Janus kinase (JAK) inhibitor
Psoriatic arthritis (PsA)
Online Access:https://doi.org/10.1186/s13075-023-03027-5

Internet

https://doi.org/10.1186/s13075-023-03027-5

Similar Items